Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Biogen is scaling back space outside Boston

By Sean Whooley | August 10, 2022

Biogen logoAccording to reports, Biogen has taken steps to cut costs following the release of its Aduhelm Alzheimer’s disease drug.

The company has moved to sublease more than 260,000 square feet at multiple locations in Massachusetts as it looks to cut $1 billion in costs, The Boston Globe reported.

Across from its Cambridge, Massachusetts, headquarters, the company plans to sublease more than 183,000 square feet in its 300 Binney Street space, while it has also made plans to sublease two floors comprising 80,000 square feet at one of two properties at 133 Boston Pond Road in Weston, Massachusetts, The Globe report said.

The Globe report credited the Boston Business Journal with first reporting the sublease news, while also saying that Biogen has “long subleased” one of its two Weston buildings to Monster, the job search website.

Biogen’s cost-cutting efforts will total an estimated $1 billion in part through an unspecified number of layoffs, the report said, including what The Globe described as “essentially its sales division” for the controversial Aduhelm Alzheimer’s drug. The Globe said Biogen had previously confirmed as many as 1,000 layoffs in March, while a spokesperson did not offer an updated total but confirmed to the publication that the company has allowed some vacant positions to remain unfilled.

The spokesperson also told the outlet that the decision to sublease the office space in Cambridge and Weston represents part of Biogen’s efforts to optimize its footprint and reduce the amount of space it takes up while considering elements like the hybrid work model.

Aduhelm has been under scrutiny since its 2021 FDA approval through an accelerated approval pathway. A recent physician survey demonstrated that nine in 10 neurologists have doubts over the therapeutic while earlier this year, the Centers for Medicare & Medicaid Services (CMS) ruled that it would limit coverage of the drug.

While sales for the drug sputtered, in May, CEO Michel Vounatsos stepped down from the corner office.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE